SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    V. Virlogeux, P. Pradat, F. Bailly, G. Funingana, F. Gonçalves, M. Maynard, K. Hartig-Lavie, M. Amiri, F. Zoulim, Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score, Journal of Viral Hepatitis, 2014, 21, 5
  2. 2
    Kevin Humphries, Jama M. Darling, A. Sidney Barritt, Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature, Digestive Diseases and Sciences, 2014,

    CrossRef

  3. 3
    Umberto Vespasiani-Gentilucci, Paolo Gallo, Antonio Picardi, Renal impairment and anemia during triple therapy, Journal of Hepatology, 2014, 60, 5, 1099

    CrossRef

  4. 4
    Véronique Loustaud-Ratti, Paul Carrier, Chanlina Vong, Marie Essig, Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir, Hepatology, 2014, 59, 5
  5. 5
    Manuel Romero-Gómez, Marina Berenguer, Esther Molina, Jose-Luis Calleja, Reply to: “Renal impairment and anemia during triple therapy”, Journal of Hepatology, 2014, 60, 5, 1100

    CrossRef

  6. 6
    A. Kyvernitakis, E. Jabbour, H. A. Torres, Sustained Virologic Response After 6 Weeks of Therapy With a First-Generation Hepatitis C Virus Protease Inhibitor, Clinical Infectious Diseases, 2014, 58, 9, 1342

    CrossRef